Biblio
Export 1085 results:
Author Title Type [ Year] Filters: First Letter Of Last Name is T [Clear All Filters]
“Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1107-1117, 2018.
, “Change of Amyloid-β 1-42 Toxic Conformer Ratio After Cerebrospinal Fluid Diversion Predicts Long-Term Cognitive Outcome in Patients with Idiopathic Normal Pressure Hydrocephalus.”, J Alzheimers Dis, vol. 63, no. 3, pp. 989-1002, 2018.
, “Characterization of Music and Photograph Evoked Autobiographical Memories in People with Alzheimer's Disease.”, J Alzheimers Dis, vol. 66, no. 2, pp. 693-706, 2018.
, “Circulating, Cell-Free Micro-RNA Profiles Reflect Discordant Development of Dementia in Monozygotic Twins.”, J Alzheimers Dis, vol. 63, no. 2, pp. 591-601, 2018.
, “Circulating miR-127-3p as a Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia.”, J Alzheimers Dis, vol. 65, no. 2, pp. 455-464, 2018.
, “Circulating Progenitor Cells Correlate with Memory, Posterior Cortical Thickness, and Hippocampal Perfusion.”, J Alzheimers Dis, vol. 61, no. 1, pp. 91-101, 2018.
, “Clinical Experience with Cerebrospinal Fluid Aβ42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia.”, J Alzheimers Dis, vol. 65, no. 4, pp. 1417-1425, 2018.
, “Clinical Experience with Cerebrospinal Fluid Aβ42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia.”, J Alzheimers Dis, vol. 65, no. 4, pp. 1417-1425, 2018.
, “Clinical Experience with Cerebrospinal Fluid Aβ42, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia.”, J Alzheimers Dis, vol. 65, no. 4, pp. 1417-1425, 2018.
, “Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.”, J Alzheimers Dis, vol. 61, no. 1, pp. 135-143, 2018.
, “A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1347-1360, 2018.
, “Co-Expression of Glia Maturation Factor and Apolipoprotein E4 in Alzheimer's Disease Brain.”, J Alzheimers Dis, vol. 61, no. 2, pp. 553-560, 2018.
, “Cognitive Function in Individuals with Normal Weight Obesity: Results from the Third National Health and Nutrition Examination Survey (NHANES III).”, J Alzheimers Dis, vol. 65, no. 1, pp. 125-135, 2018.
, “Common Variant in PLD3 Influencing Cerebrospinal Fluid Total Tau Levels and Hippocampal Volumes in Mild Cognitive Impairment Patients from the ADNI Cohort.”, J Alzheimers Dis, vol. 65, no. 3, pp. 871-876, 2018.
, “Common Variant in PLD3 Influencing Cerebrospinal Fluid Total Tau Levels and Hippocampal Volumes in Mild Cognitive Impairment Patients from the ADNI Cohort.”, J Alzheimers Dis, vol. 65, no. 3, pp. 871-876, 2018.
, “Common Variant in PLD3 Influencing Cerebrospinal Fluid Total Tau Levels and Hippocampal Volumes in Mild Cognitive Impairment Patients from the ADNI Cohort.”, J Alzheimers Dis, vol. 65, no. 3, pp. 871-876, 2018.
, “Comparison of Different Hypotheses Regarding the Spread of Alzheimer's Disease Using Markov Random Fields and Multimodal Imaging.”, J Alzheimers Dis, vol. 65, no. 3, pp. 731-746, 2018.
, “Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice.”, J Alzheimers Dis, vol. 63, no. 1, pp. 115-130, 2018.
, “Is Computerized Working Memory Training Effective in Healthy Older Adults? Evidence from a Multi-Site, Randomized Controlled Trial.”, J Alzheimers Dis, vol. 65, no. 3, pp. 931-949, 2018.
, “Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.”, J Alzheimers Dis, vol. 61, no. 1, pp. 169-183, 2018.
, “Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.”, J Alzheimers Dis, vol. 61, no. 1, pp. 169-183, 2018.
, “A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1181-1198, 2018.
, “Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation.”, J Alzheimers Dis, vol. 64, no. 2, pp. 597-606, 2018.
, “Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation.”, J Alzheimers Dis, vol. 64, no. 2, pp. 597-606, 2018.
, “Deficits in Regional Cerebral Blood Flow on Brain SPECT Predict Treatment Resistant Depression.”, J Alzheimers Dis, vol. 63, no. 2, pp. 529-538, 2018.
,